In an attempt to characterize the clonal evolution and frequency of BTK mutations for CLL patients progressing on ibrutinib or acalabrutinib, Woyach et al. identified that BTK mutations occur in 66% of acalabrutinib- and 37% of ibrutinib-treated patients [59]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.